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Abstract: Inactivating mutations in ABCC6 underlie the rare hereditary mineralization disorder
pseudoxanthoma elasticum. ABCC6 is an ATP-binding cassette (ABC) integral membrane protein
that mediates the release of ATP from hepatocytes into the bloodstream. The released ATP is
extracellularly converted into pyrophosphate, a key mineralization inhibitor. Although ABCC6 is
firmly linked to cellular ATP release, the molecular details of ABCC6-mediated ATP release remain
elusive. Most of the currently available data support the hypothesis that ABCC6 is an ATP-dependent
ATP efflux pump, an un-precedented function for an ABC transporter. This hypothesis implies
the presence of an ATP-binding site in the substrate-binding cavity of ABCC6. We performed an
extensive mutagenesis study using a new homology model based on recently published structures of
its close homolog, bovine Abcc1, to characterize the substrate-binding cavity of ABCC6. Leukotriene
C4 (LTC4 ), is a high-affinity substrate of ABCC1. We mutagenized fourteen amino acid residues
in the rat ortholog of ABCC6, rAbcc6, that corresponded to the residues in ABCC1 found in the
LTC4 binding cavity. Our functional characterization revealed that most of the amino acids in
rAbcc6 corresponding to those found in the LTC4 binding pocket in bovine Abcc1 are not critical
for ATP efflux. We conclude that the putative ATP binding site in the substrate-binding cavity of
ABCC6/rAbcc6 is distinct from the bovine Abcc1 LTC4 -binding site.
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1. Introduction
Inactivating mutations in the gene encoding ATP-binding cassette (ABC) subfamily C
member 6 (ABCC6) underlie the autosomal recessive disease pseudoxanthoma elasticum
(PXE, OMIM #264800) [1–3], characterized by ectopic mineralization in the skin, eyes, and
vascular system [4–6]. PXE is a slowly progressing connective tissue disorder that affects
approximately 1 in 50,000 individuals worldwide [7]. There is currently no specific and
effective therapy for PXE and the disease slowly progresses after initial diagnosis [8].
ABCC6 is predominantly expressed in the liver [9] where it mediates the release of
ATP from hepatocytes into the bloodstream [10,11]. Outside the hepatocytes, yet still in the
liver niche, the released ATP is converted into AMP and the mineralization inhibitor pyrophosphate (PPi), by ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) [12].
The absence of ABCC6-mediated ATP release in both PXE patients and Abcc6 null mice
results in plasma PPi levels that are < 40% of those found in ABCC6-proficient individuals [11], providing a plausible biochemical explanation for their ectopic mineralization.
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Moreover, plasma PPi levels decline during pregnancy, which might explain the increased
risk of vascular calcification in multiparous individuals [13]. Recent data indicate that ATP
efflux by the progressive ankylosis protein (ANK) is also a major determinant of plasma
PPi levels [14]. Intriguingly, an ABC protein other than ABCC6 has been reported to also
be involved in cellular ATP release, albeit indirectly, as two ABCG1 variants were found to
control volume-regulated anion channel-dependent ATP release by regulating cholesterol
levels in the plasma membrane [15]. Neither of these ABCG1 variants, however, have been
implicated in the pathology of PXE.
Although low levels of circulating PPi explain why PXE patients suffer from ectopic
mineralization, the molecular details of ABCC6-mediated ATP release remain elusive. Most
ABC proteins of the C-branch function as ATP-dependent efflux transporters, though there
are several exceptions. Thus, ABCC7 is the ATP-gated chloride channel cystic fibrosis
transmembrane conductance regulator (CFTR) with inactivating mutations causing cystic fibrosis [16], and ABCC8 and ABCC9 are regulatory subunits of complex potassium
channels [17].
Most of the currently available data indicate that ABCC6 is an ATP-dependent ATP
efflux transporter: ATP efflux rates from ABCC6-transfected HEK293 cells are very similar
to rates at which ABCC1, ABCC2, and ABCC3 transport morphine-3-glucuronide out
of cells [18]. Moreover, our recent work indicates ABCC6 does not function as an ATP
channel [19] and nor does it induce the exocytosis of ATP-loaded vesicles (our unpublished
data). ABCC6 was initially implicated in the transport of glutathione conjugates in in vitro
vesicular uptake assays [20,21] but these results proved difficult to reproduce in later
studies [6].
In 2017, the structure of LTC4 -bound bovine Abcc1 (bAbcc1) in the ATP-free state, with
a bipartite transmembrane cavity open towards the cytosol (inward-facing) was reported
using cryogenic electron microscopy (cryoEM) [22]. This report was later followed by the
cryoEM structure of the ATP-bound, outward-facing state of bAbcc1, with the transmembrane cavity open to the opposite side of the membrane [23]. Given that (1) ABCC6 shares
most sequence similarity with ABCC1 [24], (2) the genes encoding both proteins arose from
a recent gene duplication [25], and (3) in vitro studies suggested both proteins might share
LTC4 as a substrate [4,21,26,27] though attempts to connect the transport of LTC4 to the
potential role of ABCC6 failed [6].
We used the ATP-free, LTC4 -bound and ATP-bound, substrate-free, bAbcc1 cryoEM
structures as templates to build inward- and outward-facing homology models of hABCC6
and rat Abcc6 (rAbcc6) as a means of identifying amino acids potentially forming the
binding cavity for ATP. Amino acids in ABCC6 at the same positions as those in bAbcc1
comprising the proposed bipartite binding cavity of LTC4 were subsequently mutated in
rAbcc6 expression vectors and the mutant rAbcc6 proteins functionally characterized to
determine if they play a role in ABCC6-dependent ATP release. Several of the introduced
mutations did not markedly alter rAbcc6 activity and thus are not essential for ATP efflux.
Strikingly, the generation of a rAbcc6 mutant in which all amino acids of the modeled
binding cavity were changed into their ABCC1 counterparts, showed ATP efflux similar to
the wild-type protein.
2. Results
2.1. Homology Models of Human and Rat ABCC6/Abcc6
ABC transporters have a common structural core that in ABCC6 and all other ABCC
subfamily members consist of transmembrane domain 1 (TMD1, encompassing transmembrane helices (TM) 6 to 11), nucleotide-binding domain 1 (NBD1), TMD2 (TM12 to 17) and
NBD2. We built a sequence alignment for TMD1-NBD1 and TMD2-NBD2 (see Supporting
Information files TMD1-NBD1_Alignment.pdf and TMD2-NBD2_Alignment.pdf), using
several orthologues of ABCC1, ABCC6, and ABCC5, for which negatively charged substrates have been reported. From these alignments, we observed a 46% and 48% sequence
identity for rAbcc6-bAbcc1 and hABCC6-bAbcc1 TMD1-NBD1, respectively, and 52% and
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Supporting Information files TMD1‐NBD1_Alignment.pdf and TMD2‐NBD2_Align‐
ment.pdf), using several orthologues of ABCC1, ABCC6, and ABCC5, for which 3nega‐
of 19
tively charged substrates have been reported. From these alignments, we observed a 46%
and 48% sequence identity for rAbcc6‐bAbcc1 and hABCC6‐bAbcc1 TMD1‐NBD1, respec‐
tively, and 52% and 53% sequence identities for rAbcc6‐bAbcc1 and hABCC6‐bAbcc1
53%
sequence identities
for rAbcc6-bAbcc1
hABCC6-bAbcc1
TMD2-NBD2,
respecTMD2‐NBD2,
respectively.
The % sequenceand
identity
calculated for
TMD1 (rAbcc6
resi‐
tively.
The
%
sequence
identity
calculated
for
TMD1
(rAbcc6
residues
298–608)
and
TMD2
dues 298–608) and TMD2 (rAbcc6 residues 933–1242) are 39% and 48%, respectively,
for
(rAbcc6 residues 933–1242) are 39% and 48%, respectively, for rAbcc6 and bAbcc1, and
rAbcc6 and bAbcc1, and 40% for TMD1 and 48% for TMD2 between hABCC6 and bAbcc1.
40% for TMD1 and 48% for TMD2 between hABCC6 and bAbcc1. Considering the high
Considering the high sequence identity with bAbcc1, we modeled the structural core for
sequence identity with bAbcc1, we modeled the structural core for rAbcc6 and hABCC6 in
rAbcc6 and hABCC6 in two distinct conformational states (Figure S1), based on the cry‐
two distinct conformational states (Figure S1), based on the cryoEM structures reported
oEM structures reported for the LTC4‐bound, ATP‐free, inward‐facing state and on the
for the LTC4 -bound, ATP-free, inward-facing state and on the ATP-bound outward-facing
ATP‐bound outward‐facing state of bAbcc1 [22,23].
state of bAbcc1 [22,23].
Consistent with their relatively high degree of sequence identity, both
Consistent with their relatively high degree of sequence identity, both hABCC6/rAbcc6
hABCC6/rAbcc6 and bAbcc1 showed a strong positive potential in the cavity along TMs
and bAbcc1 showed a strong positive potential in the cavity along TMs of both TMD1 and
of both TMD1 and TMD2 (Figure 1). Another common feature of hABCC6/rAbcc6 and
TMD2 (Figure 1). Another common feature of hABCC6/rAbcc6 and bAbcc1 is the presence
bAbcc1 is the presence of a more negative potential on the extracellular end of the TMDs
of a more negative potential on the extracellular end of the TMDs (Figure S2A), which
(Figure S2A),
which following
the conformational
change
to the ATP‐bound,
outward‐
following
the conformational
change
to the ATP-bound,
outward-facing
state, appears
less
facing
state,
appears
less
prominent
(Figure
S2).
prominent (Figure S2).
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Figure
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ATP‐free,
inward‐facing
(A)
rAbcc6
static potential mapped on the molecular surface of the ATP-free, inward-facing (A) rAbcc6 model,
model, (B) hABCC6 model, and (C) bAbcc1 cryoEM structure. The isovalue was set at −10 kBT/e
(B) hABCC6 model, and (C) bAbcc1 cryoEM structure. The isovalue was set at −10 kB T/e for
for the negative potential (red) and +10 kBT/e for the positive potential (blue). For each transporter,
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byTMDs,
side. The
region of thedomains;
transporters
embedded
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the membrane
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by shown
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embedded
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transmembrane
domains;
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ICLs, intracellular loops, i.e., the intracellular extension of the TMDs; NBD1 and NBD2, nucleotide
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binding domain
andthe
2. intracellular extension of the TMDs; NBD1 and NBD2, nucleotide binding
domain 1 and 2.

In the transmembrane cavity of bAbcc1, several residues have been proposed as par‐
In thein
transmembrane
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the recognitioncavity
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4 through a network of hydrogen bonds, salt bridges,
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the
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bonds, not
salt all
bridges,
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and Table
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(Figure
S3,
Figure
2
and
Table
1)
[22],
although
not
all
of the
proposed interactions are supported by biochemical studies [28,29].
proposed interactions are supported by biochemical studies [28,29].
Table 1. Amino acid residues in rat and human ABCC6, human ABCC1 and human ABCC5 at the
Table
Amino proposed
acid residues
in rat
human
ABCC6,
ABCC1
and
ABCC5
at the
same 1.
positions
to form
theand
LTC
4 binding
cavityhuman
in bAbcc1.
In the
lasthuman
column
it is indicated
same
positions
proposed to form
LTCand
cavity in bAbcc1.
In the
last column
it is indicated
to which
transmembrane
helixthe
(TM)
transmembrane
domain
(TMD)
the residues
belong.
4 binding
bovine Abcc1; helix
hABCC1,
human
ABCC1; hABCC6,
ABCC6;
rAbcc6,
ratbAbcc1,
Abcc6;
tobAbcc1,
which transmembrane
(TM) and
transmembrane
domainhuman
(TMD) the
residues
belong.
hABCC5,
human
ABCC5.human ABCC1; hABCC6, human ABCC6; rAbcc6, rat Abcc6; hABCC5,
bovine
Abcc1;
hABCC1,
human ABCC5.
bAbcc1
hABCC1
hABCC6
rAbcc6
hABCC5
TM Helix
K332
K332
L318
L316
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TMD1,
TM6
bAbcc1
hABCC1
hABCC6
rAbcc6
hABCC5
TM Helix
H335
H335
S321
S319L316
T189L186
TMD1,
K332
K332
L318
TMD1,TM6
TM6
L381
L381
E367
E365
L236
TMD1, TM7
H335
H335
S321
S319
T189
TMD1, TM6
F385
F385
M371
M369
W240
TMD1, TM7
L381
L381
E367
TMD1,TM8
TM7
Y440
Y440
Y426
H424E365
V293L236
TMD1,
F385
F385
M371
M369
W240
TMD1, TM7
Y440

Y440

Y426

H424

V293

TMD1, TM8

T550

T550

L536

L534

V403

TMD1, TM10

R1196
Y1242
N1244
W1245
R1248

R1197
Y1243
N1245
W1246
R1249

R1169
T1215
Q1217
W1218
R1221

R1168
T1214
Q1216
W1217
R1220

R1096
L1142
Q1144
F1145
R1148

TMD2, TM16
TMD2, TM17
TMD2, TM17
TMD2, TM17
TMD2, TM17
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The residues in the cavity are proposed to form a bipartite binding site [30] with a
more prominent positive charge on one side (residues K332, H335, L381, F385, Y440, F594
of TMD1, and R1196, N1244, and R1248 of TMD2, namely the P‐pocket) to bind the hy‐
Table 1. Cont.
drophilic glutathione moiety of LTC4 and a more hydrophobic pocket (namely, the H‐
of TMD1, and
pocket)
to accommodate
tail of LTC4 (residues
bAbcc1
hABCC1 the lipid
hABCC6
rAbcc6 T550, W553
hABCC5
TMM1092,
Helix
Y1242,
W1245
of
TMD2)
[22].
Our
goal
was
to
address
if
ABCC6
(the
corresponding
resi‐
W553
W553
F539
F537
A406
TMD1, TM10
dues shown in Figure 2 for rAbcc6 and in Figure S3 for hABCC6), in both the ATP‐free
F594
F594
K579
K578
Q432
TMD1, TM11
and ATP‐bound states, might be involved in ATP interaction and efflux. First, we ana‐
M1092
M1093
S1065
T1064
M992
TMD2,
lyzed how the proposed P‐pocket and H‐pocket residues are conserved across
theTM14
se‐
quences
account to build
the models. R1168
The analysis ofR1096
the sequenceTMD2,
alignment
R1196 taken into
R1197
R1169
TM16
(Supplemental information files TMD1‐NBD1_Alignment.pdf and TMD2‐NBD2_Align‐
Y1242
Y1243
T1215
T1214
L1142
TMD2, TM17
ment.pdf) showed that bAbcc1 W553 and W1245 in the hydrophobic pocket are conserved
N1244
N1245
Q1216
Q1144to rAbcc6
TMD2,
TM17
among
the ABCC6,
ABCC1, and Q1217
ABCC5 sequences,
and correspond
residues
W1245
W1246and W1217
W1218
W1217
TMD2,
TM17
F537
(TM10 in TMD1)
(TM17 in TMD2)
(Figure 2). InF1145
the P‐pocket,
the more
conserved
residues
are
bAbcc1
R1196,
R1248,
and
N1244,
which
correspond
to
rAbcc6
R1248
R1249
R1221
R1220
R1148
TMD2, TM17
R1168 (TM16 in TMD2), R1220 and Q1216 (TM17 in TMD2) (Figure 2).
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Figure 2. rAbcc6 residues in the transmembrane cavity corresponding to those in the bAbcc1 cavity
Figure 2. rAbcc6 residues in the transmembrane cavity corresponding to those in the bAbcc1 cavity
surrounding LTC4. View from the extracellular side of the transmembrane cavity of the inward‐
surrounding
LTC4(A)
. View
the extracellular
side of the
cavity
of residues
the inward-facing,
facing, ATP‐free
andfrom
outward‐facing,
ATP‐bound
(B)transmembrane
models of rAbcc6.
The
corre‐
ATP-free
ATP-bound
(B) models
of rAbcc6.
The
corresponding
4 binding cavity
are shown
as sticks
in residues
light cyan
for TMD1
sponding(A)
to and
thoseoutward-facing,
of the bAbcc1 LTC
toand
those
of the
in teal
for bAbcc1
TMD2. LTC4 binding cavity are shown as sticks in light cyan for TMD1 and in teal
for TMD2.

The degrees of similarity for the other residues of the bAbcc1 P‐ and H‐pockets vary
across
ABCC1,in
ABCC6,
and ABCC5
sequences
considered
in the binding
alignment.
Charged
Thetheresidues
the cavity
are proposed
to form
a bipartite
site
[30] with
that are not
conserved
are: on
(1) bAbcc1
whichK332,
is a leucine
ABCC6
(L316
aresidues
more prominent
positive
charge
one sideK332,
(residues
H335,inL381,
F385,
Y440,
in
rAbcc6)
and
ABCC5,
(2)
H335
in
hABCC1/bAbcc1,
which
is
a
serine
in
the
F594 of TMD1, and R1196, N1244, and R1248 of TMD2, namely the P-pocket) to bind
hABCC6/rAbcc6
sequences, moiety
and (3) of
rAbcc6
is a glutamatepocket
only in
ABCC6the
the
hydrophilic glutathione
LTC4 E365,
and a which
more hydrophobic
(namely,
sequences
and
a
leucine
in
hABCC1
(L381
in
bAbcc1)
and
ABCC5.
Of
note,
in
hABCC1,
H-pocket) to accommodate the lipid tail of LTC4 (residues T550, W553 of TMD1, and
K332, and
to aW1245
lesser extent
H335,
are Our
indispensable
foraddress
LTC4 binding
and(the
transport,
indi‐
M1092,
Y1242,
of TMD2)
[22].
goal was to
if ABCC6
corresponding
cating
K332
and
H335
are
crucial
amino
acid
residues
in
its
LTC
4‐binding site [29,31]. An
residues shown in Figure 2 for rAbcc6 and in Figure S3 for hABCC6), in both the ATP-free

and ATP-bound states, might be involved in ATP interaction and efflux. First, we analyzed
how the proposed P-pocket and H-pocket residues are conserved across the sequences taken
into account to build the models. The analysis of the sequence alignment (Supplemental
information files TMD1-NBD1_Alignment.pdf and TMD2-NBD2_Alignment.pdf) showed
that bAbcc1 W553 and W1245 in the hydrophobic pocket are conserved among the ABCC6,
ABCC1, and ABCC5 sequences, and correspond to rAbcc6 residues F537 (TM10 in TMD1)
and W1217 (TM17 in TMD2) (Figure 2). In the P-pocket, the more conserved residues are
bAbcc1 R1196, R1248, and N1244, which correspond to rAbcc6 R1168 (TM16 in TMD2),
R1220 and Q1216 (TM17 in TMD2) (Figure 2).
The degrees of similarity for the other residues of the bAbcc1 P- and H-pockets vary
across the ABCC1, ABCC6, and ABCC5 sequences considered in the alignment. Charged
residues that are not conserved are: (1) bAbcc1 K332, which is a leucine in ABCC6 (L316 in
rAbcc6) and ABCC5, (2) H335 in hABCC1/bAbcc1, which is a serine in the hABCC6/rAbcc6
sequences, and (3) rAbcc6 E365, which is a glutamate only in ABCC6 sequences and a
leucine in hABCC1 (L381 in bAbcc1) and ABCC5. Of note, in hABCC1, K332, and to a lesser
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extent H335, are indispensable for LTC4 binding and transport, indicating K332 and H335
are crucial amino acid residues in its LTC4 -binding site [29,31]. An additional alignment
performed
sequences
of human
ABC transporters
the C
subfamilyofconfirmed
additional using
alignment
performed
using sequences
of humanofABC
transporters
the C
these
observations
and
demonstrate
exceptionally
high
conservation
of
R1168
and
R1220
subfamily confirmed these observations and demonstrate exceptionally high conservation
(numbering
of
rAbcc6)
among
ABCC
proteins
(Figure
S5).
of R1168 and R1220 (numbering of rAbcc6) among ABCC proteins (Figure S5).
2.2.
of Single
SingleAmino
AminoAcid
AcidrAbcc6
rAbcc6Mutants
Mutants
2.2.Functional
Functional Analysis
Analysis of
Our
whetherthe
theresidues
residuesininABCC6
ABCC6
corresponding
to those
Our aim
aim was
was to determine
determine whether
corresponding
to those
thought
in interaction
interactionwith
withthe
thephysiological
physiological
ABCC1
substrate
LTC
thoughtto
tobe
be important
important in
ABCC1
substrate
LTC
4, play
4 , play
aarole
ATP efflux.
efflux.We
Weused
usedrAbcc6
rAbcc6ininthese
these
studies,
because
it has
rolein
inABCC6-mediated
ABCC6‐mediated ATP
studies,
because
it has
higher
hABCC6
[10].
ATP
and
other
nucleoside
triphosphates
higheractivity
activityininHEK293
HEK293cells
cellsthan
than
hABCC6
[10].
ATP
and
other
nucleoside
triphos‐
phates (NTPs),
the putative
physiological
substrates
of ABCC6,
carry multiple
negative
(NTPs),
the putative
physiological
substrates
of ABCC6,
carry multiple
negative
charges.
charges.
We
hypothesized
such
negatively
charged
substrates
may
be
“coordinated”
by
We hypothesized such negatively charged substrates may be “coordinated” by positively
positively
charged
residues
in
the
substrate
binding
cavity
of
rAbcc6.
Therefore,
posi‐
charged residues in the substrate binding cavity of rAbcc6. Therefore, positively charged
tively acid
charged
amino(i.e.,
acidlysine,
moieties
(i.e., lysine,
histidine)
at these
positions,
amino
moieties
arginine,
and arginine,
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2.3. Subcellular Localization of the Single Amino Acid rAbcc6 Mutants That Showed Reduced
ATP Efflux Activity
To exert its function, ABCC6 needs to reside in the plasma membrane. Confocal
microscopy demonstrated that all rAbcc6 mutants with reduced activity routed to the
plasma membrane, similar to wild-type rAbcc6 (Figure 6). This indicates that reduced
plasma membrane localization was not the underlying cause of the reduced activity of
these rAbcc6 mutants. Notably, although a significant proportion of the rAbcc6 mutant
proteins also resided in intracellular compartments, this was not different from wild-type
rAbcc6 and is consistent with our previous observations [19].

Figure 6. Subcellular localization of rAbcc6 mutants with reduced ATP efflux activity. Representative images of the
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subcellular localization of wild-type and single mutant rAbcc6 in HEK293 cells, as determined by confocal microscopy
using the K14 anti-rAbcc6 rabbit polyclonal antibody. Red: Na+ /K+ -ATPase, a marker for the plasma membrane; Green:
rAbcc6.; Blue: DAPI nuclear staining; wt rAbcc6: wild-type rAbcc6, control: parental HEK293 cells. All scale bars represent
30 µm.

2.4. Functional Consequences of Changing All 11 Amino Acids of the Modeled rAbcc6
Substrate-Binding Site into Those That Comprise the bAbcc1 LTC4 Binding Site
As most mutants with single amino acid changes in the modeled rAbcc6 substrate
binding cavity retained at least 25% activity, we wondered what the consequences would
be if the entire modeled substrate binding cavity was altered such that it more closely
mimicked that of ABCC1. Of the fourteen amino acids corresponding to those in the bAbcc1
cryoEM structure forming the LTC4 -binding cavity, three are identical in rAbcc6 (rAbcc6
R1168, W1217 and R1220) (Table 1 and Figure 2). Thus, the remaining eleven amino acids
of the modeled substrate-binding cavity were changed into residues found in bAbcc1 at
the same positions (L316K, S319H, E365L, M369F, H424Y, F537W, L534T, K578F, T1064M,
T1214Y, and Q1216N) to generate a rAbcc6 mutant protein we have termed rAbcc6-11aa.
As shown in Figure 7A, the rAbcc6-11aa was expressed at about 6.5-fold lower levels
than the wild-type rAbcc6 protein when overexpressed in HEK293 cells and appeared
to have a faster electrophoretic mobility (Figure 7A). The reason for the altered mobility
of rAbcc6-11a is not known but may be due to changes in glycosylation or other posttranslational modification. If underglycosylated, the mutant rAbcc6-11aa protein may have
a faster turn-over time thus explaining why it is expressed at lower levels than the wildtype protein. However, even if the mutations caused some misfolding of the transporter
during its biosynthesis that impaired its glycosylation, the altered protein structure has
remained stable enough to traffic to the plasma membrane where it can still carry out
active transport. Thus, rAbcc6-11aa still mediated ATP release, as illustrated by both PPi
accumulation in the medium and by real-time ATP efflux assays (Figure 7C,D, respectively).
After adjustment for lower protein levels, rAbcc6-11aa seemed to even display higher
activity than the wild-type protein. These data indicate that changing these 11 amino acids
may have affected the stability of rAbcc6 but had minimal effect on the intrinsic activity of
the protein. Consistent with the significant activity of the rAbcc6-11aa mutant protein, its
abundance in the plasma membrane was also relatively high (Figure 7B).
We next set out to test if the rAbcc6-11aa mutant with the hABCC1/bAbcc1 LTC4 binding cavity residues transports LTC4 . Of note, an initial characterization of hABCC6
indicated it could transport LTC4 [6], although this was not the case for its ortholog
rAbcc6 [35]. Nevertheless, we reasoned that introducing the amino acids in bAbcc1 thought
to form the bipartite LTC4 -binding cavity at the corresponding positions in rAbcc6 might
establish LTC4 transport in the latter ABC transporter. The cellular ATP efflux capacity
of the rAbcc6-11aa indicated the protein retained activity. However, in vitro vesicular
transport experiments (widely held to be the gold-standard to confirm that a molecule is a
substrate of a specific ABC transporter) failed to demonstrate LTC4 transport by the rAbcc611aa protein (data not shown). Low levels of LTC4 transport might have been missed,
however, because of the low expression levels of rAbcc6-11aa in our system (HEK293 cells).
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We next set out to test if the rAbcc6‐11aa mutant with the hABCC1/bAbcc1 LTC4‐
3. Discussion
binding cavity residues transports LTC4. Of note, an initial characterization of hABCC6
ABC transporters use the energy derived from ATP hydrolysis to mediate transport of
indicated it could transport LTC4 [6], although this was not the case for its ortholog rAbcc6
a wide range of substrates across membranes. Several members of the ABCC subfamily
[35]. Nevertheless, we reasoned that introducing the amino acids in bAbcc1 thought to
have been studied for their role in drug resistance and human diseases. Many of these transform the bipartite LTC4‐binding cavity at the corresponding positions in rAbcc6 might
porters translocate negatively charged solutes. For example, ABCC1 transports organic
establish LTC4 transport in the latter ABC transporter. The cellular ATP efflux capacity of
anions, including LTC4 , a cysteinyl leukotriene with proinflammatory properties [26,27,36],
the rAbcc6‐11aa indicated
the protein retained activity. However, in vitro vesicular
while ABCC5 transports cyclic nucleotides such as cAMP and cGMP [37,38], important
transport experiments (widely held to be the gold‐standard to confirm that a molecule is
for signal transduction. Most of the available data indicate ABCC6 transports ATP and
a substrate of a specific ABC transporter) failed to demonstrate LTC4 transport by the
other NTPs out of cells [10,11,39,40]. However, even now, ABCC6-mediated ATP efflux
rAbcc6‐11aa protein (data not shown). Low levels of LTC4 transport might have been
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has not been shown in vesicular uptake experiments, widely used to demonstrate that
a given compound is actively transported by an ABC transporter [6,19]. Being involved
in the efflux of ATP confers a unique physiological role for ABCC6 among ABCC transporters [19]. We hypothesized that the substrate-binding cavity of ABCC6 is also unique
among ABC transporters, involving amino acids that are not necessarily evolutionarily
conserved among members of the ABCC subfamily. To address this, we built homology
models of hABCC6/rAbcc6 in two different conformations (ATP-free, inward-facing and
ATP-bound, outward-facing) (Figure S1). The previous homology modeling studies of
ABCC6 were performed using available structures of bacterial ABC transporters or the
related mouse P-glycoprotein, a member of the ABCB subfamily [41,42]. Here, we used
the cryoEM structures of bAbcc1 [22,23], and compared the residues in the bipartite LTC4
binding pocket of bAbcc1 with other ABCC1 sequences, as well as ABCC6 and ABCC5
sequences (see the Supporting Information alignment files). This choice was dictated by
the shared ability of ABCC1, ABCC5 and ABCC6 transporters to translocate negatively
charged substrates including cyclic nucleotides, as well as an early study reporting the
ability of hABCC6 to transport LTC4 [20], which suggested there may be similarities in
substrate recognition by hABCC6, hABCC1, and ABCC5. Of note, however, is that rAbcc6
has never been shown to transport LTC4 [35] and later studies also failed to confirm LTC4
transport by hABCC6 [6]. Nevertheless, the overall electrostatic properties of the transmembrane cavity appear remarkably similar between the hABCC6/rAbcc6 models and
the bAbcc1 cryoEM structures, with a strong positive potential that might contribute to
the driving force for the uptake of negatively charged substrates from the cytosol (Figure 1
and Figure S2). Interestingly, the negative potential on the extracellular end of the TMDs
(Figure S2A) appeared less prominent following the conformational change to the ATPbound state (Figure S2B), possibly facilitating the negatively charged ATP to leave the
substrate binding cavity. Among the bAbcc1 residues found in the proposed LTC4 -binding
cavity (Table 1) are three residues that are identical to the corresponding R1168, W1217,
and R1220 in rAbcc6 (Figure 2 and Figure S4), which are conserved among all human
ABCC transporters (Figure S4) and the sequences considered in this study for model
building, likely indicating a common function in maintaining the integrity of the substrate
binding cavity. In the ATP-free, inward-facing homology model, their side chain faces
the main cavity, and the residues belong to TM helices 16 and 17 of TMD2, known to
be crucial for substrate binding and transport in ABCC1 [32,43]. Interestingly, in ABCC1
substitutions of W1246 (corresponding to rAbcc6 W1217) adversely affects transport of
estradiol-17β-glucuronide and methotrexate but not of LTC4 [29,43], also implicating a
role of this amino acid in transporter substrate selectivity. Furthermore, even conservative
same charge substitutions of R1197 and R1249 in hABCC1 cause a global loss of transport
activity [32].
We proceeded with functional studies to test if the putative transmembrane ATPbinding site of ABCC6 overlaps with the LTC4 -binding cavity of bAbcc1 using a rAbcc6
model system [22]. Of the fourteen single amino acid changes introduced into the putative ABCC6 substrate binding cavity, five were found to reduce ABCC6-dependent ATP
release by >75%, M369, L534, R1168, T1214, and R1220. Mutating the amino acid residue
corresponding to rAbcc6 L534 in ABCC1 (T550) did not affect organic anion transport [44].
In contrast, even conservative mutations of hABCC1 F385 and Y1243 [45] (corresponding to M369 and T1214 in rAbcc6) adversely affected the transport capacity of one or
more organic anions by hABCC1 (Unpublished, Conseil and Cole). Regarding the rAbcc6
R1168 position, previous studies (Table S2) have shown that opposite charge but also likecharge substitutions of hABCC1 at R1197, corresponding to rABCC6 R1168 and hABCC6
R1169, respectively, substantially reduced overall organic anion transport activity (all 4
organic anion substrates tested) as well as LTC4 binding [32]. Regarding rAbcc6 R1220,
mutations of the corresponding R1221 in hABCC6 have been reported to be disease causing (R1221C) [46–48] and pathogenic (R1221H) [47,49]. The corresponding amino acid in
hABCC1, R1249, is crucial for overall organic anion transport activity as well, not just
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glutathione-dependent binding of substrates and transport of LTC4 [32,33]. In hABCC2,
the analogous amino acid R1257 is also indispensable for activity, as the mutant protein
is deficient in glutathione conjugate transport, despite correctly routing to the plasma
membrane [50]. In hABCC4, substitution of R998, which is analogous to R1221 in hABCC6
(and R1249 in hABCC1), by alanine completely abolishes the transport of cyclic guanosine
monophosphate (cGMP) [51]. Based on the fact that the rAbcc6 R1168 and R1220 are highly
conserved in ABCC1-6 and that the mutation of these residues hampers the transport function in the paralogs, we consider it likely that the presence of the charged residues at these
positions is indispensable for all ABCC proteins and the requirement for a positive charged
residue at this position is not specific to ABCC6. The other residues corresponding to those
that form the binding cavity for LTC4 in bAbcc1 had less impact on the rAbcc6-mediated
ATP efflux. Of these, only L316A and H424A had activity that was <50% that of wild-type
rAbcc6 (Figure 4). Somewhat surprisingly, despite evidence of misfolding, the mutant
rAbcc6-11aa protein containing the same LTC4 binding cavity amino acids as bAbcc1 was
still functional and able to efflux ATP. This suggests that the amino acids corresponding to
those proposed to form the bAbcc1 LTC4 binding cavity, in ABCC6/rAbcc6 are not essential
for interaction with or the recognition of its physiological substrate, ATP. Our conclusion,
therefore, is that the binding site for ATP in the transmembrane cavity of ABCC6 is clearly
distinct from the LTC4 binding cavity in bAbcc1. The possible exceptions are two highly
conserved positively charged residues described above, namely rAbcc6 R1168 and R1220,
which are common to the substrate-binding cavity of the ABCC transporters characterized
and likely are essential for proper folding and assembly into a transport competent protein.
Despite the fact that ABCC1 and ABCC6 arose from a recent gene duplication, simple
evolution of a common substrate-binding site most likely does not explain the structurally
very distinct substrates effluxed by the two proteins.
The molecular details of ABCC6-mediated cellular ATP release remain unknown.
As outlined above, an attractive hypothesis is that ABCC6 functions as an ATP-dependent
ATP efflux pump. There are three sets of observations that support the idea that ABCC6
is an ATP efflux pump. First, most members of the C-branch of the ABC superfamily,
including ABCC60 s closest homolog ABCC1, are bona fide organic anion efflux transporters [24,26,52] and ABCC6 has been shown to transport several organic anions in vitro,
albeit sluggishly [6]. Second, the ATP efflux rates found in HEK293-ABCC6 cells [10] are
compatible with a direct transport mechanism for ATP as these rates are very similar to the
rates by which ABCC1, ABCC2, and ABCC3 pump morphine-3-glucuronide out of transfected HEK293 cells [18]. Third, ATP efflux from ABCC6-containing cells can be blocked by
the general ABCC transport inhibitors benzbromarone, indomethacin and MK571 (data
not shown).
As mentioned, vesicular transport experiments are often used to establish substrates
of ABC transporters [24]. However, such assays have so far failed to directly demonstrate
the ABCC6-dependent transport of radiolabeled ATP into inside-out membrane vesicles.
We can, therefore, not completely exclude the possibility that ABCC6 mediates cellular ATP
release other than by direct transport. Purification of ABCC6 and subsequent reconstitution
in proteoliposomes should provide a cleaner experimental system to study ATP transport,
for instance by using dual color fluorescence burst analysis (DCFBA) [53], a technique that
has a more favorable signal-to-noise ratio than the standard vesicular transport assays
that employ radiolabeled ATP. The elucidation of the molecular structure of ABCC6, for
instance by cryoEM, might also in the future provide clues about the molecular mechanism
by which ABCC6 mediates ATP release. Despite many years of intense work on ABCC6,
this ABC protein has not given many of its secrets away.
4. Materials and Methods
4.1. Model Building
We built homology models for the structural ABC transporter core of hABCC6 and
rAbcc6, including residues of TMD1, NBD1, TMD2, and NBD2. First, we generated a multi-
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ple sequence alignment (MSA) using MAFFT [54] including the sequences of the hABCC6,
hABCC1, and hABCC5 proteins from multiple organisms (Table S1), retrieved from UniProtKB [55]. Based on the alignment of hABCC6 and rAbcc6 sequences with bAbcc1, homology
models of hABCC6 and rAbcc6 were generated with Modeller 9v15 [56], using the inwardand outward-facing cryoEM structures of bAbcc1 as templates [22,23]. For hABCC6 and
rAbcc6, 20 models were generated for both the inward- and the outward-facing states,
by applying a slow refinement protocol and 20 cycles of simulated annealing as in our
previous work on hABCC7 (CFTR) [57]. For the inward-facing state, the ABCC6 models
were generated considering the presence of LTC4 in the template. The final hABCC6 and
rAbcc6 models for each conformation were chosen based on the Discrete Optimized Protein
Energy (DOPE) value implemented in Modeller. The rAbcc6 and hABCC6 models are provided in the Supporting Information as PDB files. The MSA is provided in the form of two
separate files, covering residues of TMD1 and NBD1 (see TMD1-NBD1_Alignment.pdf),
and residues of TMD2 and NBD2 (see TMD2-NBD2_Alignment.pdf). These files were
generated using Jalview [58] and the residues are colored according to the Clustal X coloring scheme implemented in Jalview. The residues highlighted in bold correspond to the
residues investigated in the present study and the rAbcc6 numbering of amino acids is
indicated. The residues of the TM helices of TMD1 and TMD2 are also annotated. The
percentage amino acid identity among bAbcc1, rAbcc6, and hABCC6 was calculated on the
TMD1-NBD1 and TMD2-NBD2 alignment using the id_table command available in Modeler. Sequences of the hABCC1 and hABCC6 proteins shown in Figure S5 were retrieved
from UniProtKB [55] and were aligned using Clustal Omega [59].
Electrostatic potential calculations were performed using the PDB2PQR and APBS
webservers [60,61], using a pH of 7 and a NaCl concentration of 0.15 M. The electrostatic potential was visually mapped on the molecular surface of the models using UCSF
Chimera [62], with a surface offset parameter of 1.4. Figure 5 was also generated using
UCSF Chimera, after calculating the cavity volumes with the 3V webserver, using the
default parameters for the Channel Finder module [34]. Other figures were generated
using PyMOL [63].
4.2. Mutagenesis
Mutagenesis was performed as described previously [19]. Briefly, mutations were introduced into the Gateway entry vector pEntr223-rAbcc6 by uracil-specific excision reagent
(USER) cloning with the primers listed in Table 2 using Phusion U PCR master mix (Thermo
Scientific, Waltham, MA, USA). PCR fragments were purified using the Nucleospin gel
and PCR cleanup kit (Macherey-Nagel, Düren, Germany) and assembled using the USER
enzyme mix (New England Biolabs, Ipswich, MA, USA), according to the manufacturer’s
instructions. Resulting circular constructs were verified by Sanger sequencing and transformed into competent E. coli DH5alpha cells. The cDNAs encoding pEnter223-rAbcc6
mutants were subsequently subcloned into a Gateway compatible pQCXIP expression
vector using LR Clonase-II (Thermo Scientific, Waltham, MA, USA).
Table 2. Primers used to generate the various rAbcc6 mutants.
Construct

Mutation

Forward Primer

Reverse Primer

rAbcc6L316A

L316A

AGCGCCGUCATTAGCGATGCCTTCAGGTTTG

ACGGCGCUGAGGGTCCCCAGCAGGAAA

rAbcc6S319A

S319A

ATTGCCGAUGCCTTCAGGTTTGCTGTT

ATCGGCAAUGACCAGGCTGAGGGTCCC

rAbcc6E365A

E365A

ACTGTTUGCCCAGCAGTACATGTACAGA

AAACAGUGTCTGTAGGCAGGCCGACAA

rAbcc6M369A

M369A

AGTACGCCUACAGAGTCAAGGTCCTGCAGATG

AGGCGTACUGCTGTTCAAACAGTGTCTG
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Table 2. Cont.
Construct

Mutation

Forward Primer

Reverse Primer

rAbcc6H424A

H424A

ATCCTCGCCCUCAACGGGCTGTGGCTGCTCTT

AGGGCGAGGAUGCTCTCGACCAGCCGCTG

rAbcc6L534A

L534A

AAGTGTCUACATTTCTGGTGGCGCTGGTTGT

AGACACTUGGAAGGACACGGCAGACACAGAGAAGAGGAAG

rAbcc6F537A

F537A

AAGTGTCUACATTTCTGGTGGCGCTGGTTGT

AGACACTUGGGCGGACACGAGAGACACAGA

rAbcc6K578Q

K578Q

AGCCAGGCCUTCCTCCCCTTCTCTGTGC

AGGCCTGGGCUTGGTTAAGGATG

rAbcc6T1064A

T1064A

AGGGCCCUGCTGACCTATGCCTTTGG

AGGGCCCUCATCTTGTCTGGGATGTCCACAT

rAbcc6R1168Q

R1168Q

ACCAGTGGCUGGCTGCCAACCTGGAGCT

AGCCACTGGUCAGCCACCAGCCTCGGGA

rAbcc6T1214A

T1214A

AGGCTCUGCAGTGGGTGGTCCGCAGCTG

AGAGCCUGTGTTACCTGGAGGGCAGCAGAAACCG

rAbcc6Q1216A

Q1216A

ACTCTGGCCUGGGTGGTCCGCAGCTGGAC

AGGCCAGAGUCTGTGTTACCTGGAGGGC

rAbcc6W1217A

W1217A

AGGCCGUGGTCCGCAGCTGGACAGATC

ACGGCCUGCAGAGTCTGTGTTACCT

rAbcc6R1220Q

R1220Q

AGTGGGTGGUCCAATCTGGAGAACAG

ACCACCCACUGCAGTCTGTGTTACCT

L316K &
S319H

AGGTCATUCACGATGCCTTCAGGTTTGCTGTTCCCAAGC

AATGACCUTGCTGAGGGTCCCCAGCAGGAAAGT

E365L &
M369F

AGCAGTACUTCTACAGAGTCAAGGTCCTGCAGATGAGGCTG

AGTACTGCUGCAGAAACAGTGTCTGTAGGCAGGCCGACAAG

H424Y

ATCCTCUACCTCAACGGGCTGTGGCTGC

AGAGGAUGCTCTCGACCAGCCGCTG

L534T

ACCGTGUCCTGGCAAGTGTCTACATTTCTGGTGGC

ACACGGUAGACACAGAGAAGAGGAAGGCGGAGGTCT

F537W

AAGTGTCUACATTTCTGGTGGCGCTGGTTG

AGACACTUGCCAGGACACGAGAGACACAGAGAAGAGGAAGGC

rAbcc611AA

K578F

ATCCTTAACUTCGCCCAGGCCTTCCTCCCCTTC

AGTTAAGGAUGCTGAGCACCGTGAGCGT

T1064M

AGGATGCUGCTGACCTATGCCTTTGGACTCCTGG

AGCATCCUCATCTTGTCTGGGATGTCCACATCCAC

T1214Y

AGTATCUGAACTGGGTGGTCCGCAGCTGG

AGATACUGTGTTACCTGGAGGGCAGCAGAAACCG

Q1216N

AACTGGGUGGTCCGCAGCTGGACAGATC

ACCCAGTUCAGAGTCTGTGTTACCTGGAGGGCAGC

4.3. Cell Culture and Generation of Mutant Cell Lines
Cell culture and generation of mutant cell lines were performed as described previously [14,19]. Briefly, HEK293 cells overproducing wild-type rAbcc6 (HEK293-rAbcc6)
and control, untransfected cells (HEK293-control) were cultured at 37 ◦ C in a 5% CO2
atmosphere under humidifying conditions in DMEM (HyClone, GE Healthcare, Chicago,
IL, USA) with 100 U pen/strep per mL (Gibco, Waltham, MA, USA) supplemented with 5%
FBS (Fisher Scientific, Waltham, MA, USA). rAbcc6 mutants cloned into the pQCXIP expression vector were transfected into HEK293 cells using the calcium phosphate precipitation
method. Transfected cells were selected in medium containing 2 µM puromycin. Cell lines
were established from clones showing high expression of the respective rAbcc6 mutants.
Of note, several clones were generated for each rAbcc6 mutation and these subclones
behaved very similarly with respect to PPi accumulation in the culture medium.
4.4. Immunoblot Analysis of Wild-Type and Mutant rAbcc6
The expression of rAbcc6 was confirmed by immunoblot analysis as described previously [19]. Briefly, cell lysates were prepared in lysis buffer (0.1% Triton-x-100, 10 mM KCl,
10 mM Tris-HCl and 1.5 mM MgCl2, pH 7.4) supplemented with protease inhibitors (EDTAfree Protease Inhibitor Cocktail, Sigma Aldrich, St. Louis, MO, USA. Samples containing
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5 µg of total protein determined by BCA assay were separated on 7.5% SDS-polyacrylamide
gels (Bio-Rad, Hercules, CA, USA and transferred to a PVDF membranes using a semi-dry
blotting system (Trans-Blot Turbo, Bio-Rad, Hercules, Ca, USA). rAbcc6 was detected
with the polyclonal K14 rabbit anti-rAbcc6 antibody (diluted 1:3000) (kind gift of Dr.
Bruno Stieger) and horseradish peroxidase (HRP)-conjugated donkey anti-rabbit secondary
antibody (1:5000) (Fisher Scientific, Waltham, MA, USA). Mouse anti-α-tubulin (1:1000)
(Sc-23948, Santa-Cruz Biotechnology, Dallas, TX, USA) followed by HRP-conjugated polyclonal rabbit anti-mouse IgG employed as secondary antibody (1:5000) (P0161, Dako,
Agilent, Santa Clara, CA, USA), was used as a protein loading control. Antibody binding
was visualized by ECL (Pierce Western blotting substrate, Thermo Scientific, Waltham,
MA, USA).
4.5. Subcellular Localization of rAbcc6 in HEK293 Cells
The localization of rAbcc6 in intact HEK293 cells was detected as described previously [19]. Briefly, HEK293 cells were seeded and grown for 2 days on 4 well µ-Slides
(ibiTreat 1.5 polymer coverslip, 80426, Ibidi) coated with poly-D-lysine. The cells were fixed
in 4% PFA and subsequently in −20 ◦ C cold methanol for 5 min each and then samples
were blocked with Protein Block (Fisher Scientific) for 60 min. Samples were then incubated
for 60 min with the polyclonal rabbit anti-rAbcc6 antibody K14 diluted 1:100 and the mouse
monoclonal anti-Na+ /K+ -ATPase antibody (ab7671, Abcam, Cambridge, UK) diluted 1:250.
Then samples were incubated for 60 min with Alexa Fluor 488-conjugated goat anti-rabbit
secondary antibody (A11008, Fisher Scientific, Waltham, MA, USA) and Alexa Fluor 568
conjugated goat anti-mouse antibody (A11004, Fisher Scientific, Waltham, MA, USA), both
diluted 1:1000. The samples were subsequently incubated with 300 nM DAPI for 5 min
to stain nuclei. The subcellular localization of wild-type and mutant forms of rAbcc6 was
then analyzed using a Nikon (Tokyo, Japan) Eclipse Ti two point-scanning laser confocal
microscope equipped with a Nikon A1R+. A Plan Fluor 40× Oil DIC H N2 objective with
a 1× optical zoom was used with 405.5, 490.0 and 561.3 nm excitation and 450/50, 525/50
and 595/50 nm emission filters, respectively. Images were acquired with the pinhole set to
1 airy unit.
4.6. Quantification of PPi Levels in Medium Samples
We have previously found that HEK293 cells endogenously express ENPP1 [10]
and that PPi accumulation in the medium can be used as a robust secondary assay to
determine the amount of ATP released by cells into the culture medium. Using two
independent assays to follow ATP efflux provides robust data on the activity of the studied
rAbcc6 mutants. PPi concentrations in cell culture medium samples were determined
as described previously [14,19]. Briefly, PPi was quantitatively converted into ATP by
incubating samples and standards in an assay containing 50 mM HEPES pH 7.4, 80 µM
MgCl2, 32 mU/mL ATP sulfurylase (New England Biolabs, Ipswich, MA, USA), and 8 µM
adenosine 5’-phosphosulfate (Santa Cruz Biotechnology, Dallas, TX, USA) at 30 ◦ C for
30 min and the reaction was terminated by incubating the samples at 90 ◦ C for 10 min. ATP
levels were then determined in the reaction mix by bioluminescence by adding BacTiterGlo
reagent (Promega, Madison, WI, USA) in a 1:1 ratio in a total volume of 40 µL. PPi
concentrations in medium samples were then calculated by interpolation from a standard
curve. The values were adjusted by subtracting background provided by controls in which
ATP sulfurylase was omitted.
4.7. Real-Time ATP Efflux Assay
The ability of the transfected HEK293 cells to release ATP into the culture medium
was determined using confluent monolayers as described previously [14,19]. In brief, the
medium was removed and replaced with 50 µL efflux buffer, consisting of 11.5 mM HEPES
(pH 7.4), 130 mM NaCl, 5 mM MgCl2, 1.5 mM CaCl2, and 11.5 mM glucose. The cells
were then incubated for 1 hr at 27 ◦ C. Next, 50 µL BactiterGlo reagent (Promega) dissolved
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in efflux buffer was added to each well. Bioluminescence was subsequently determined
in real time in a Flex Station 3 microplate reader (Molecular Devices, San Jose, CA, USA)
as detailed previously [14,19]. The real-time ATP efflux assay was run at 27 ◦ C for the
first 1 h and then at 37 ◦ C for 2 hr. The initial low temperature allowed endogenous
ecto-nucleotidases to degrade the Abcc6-independent background ATP efflux induced by
the medium change.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22136910/s1, Figure S1: Structural models of rABCC6 and hABCC6. Figure S2: Electrostatic
potential at the extracellular end of the TMDs for ABCC6 and ABCC1, Figure S3: The LTC4 binding
cavity in bABCC1 and hABCC6, Figure S4: Alignment of ABCC1-6 amino acid sequences. Table S1:
List of the ABCC1 and ABCC6 sequences and their corresponding UniProtKB codes used to generate
the alignment for the homology models. Table S2: Functional consequences of mutating rAbcc6 R1168
and R1220 and corresponding residues in hABCC6, hABCC1 and hABCC2. Supporting information files: TMD1-NBD1_Alignment.pdf, TMD2-NBD2_Alignment.pdf, hABCC6_inward-facing.pdb,
hABCC6_outward-facing.pdb, rABCC6_inward-facing.pdb, rABCC6_outward-facing.pdb.
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